68Ga-DOTATATE PET/CT for Neuroblastoma Staging: Utility for Clinical Use
| Autor: | Jim O'Doherty, Mehdi Djekidel, Ata Ur Rehman Maaz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
PET-CT Radiological and Ultrasound Technology Coronavirus disease 2019 (COVID-19) business.industry Concordance General Medicine Neuroendocrine tumors medicine.disease Novel agents Neuroblastoma Medicine Radiology Nuclear Medicine and imaging Radiology 68Ga-DOTATATE Ct imaging business |
| Zdroj: | Journal of Nuclear Medicine Technology. 49:265-268 |
| ISSN: | 1535-5675 0091-4916 |
| Popis: | Metaiodobenzylguanidine (MIBG) imaging has been the standard for neuroblastoma staging for many decades. Novel agents such as 18F-DOPA and 68Ga-DOTATATE are being used nowadays in academic centers. During the coronavirus disease 2019 (COVID-19) pandemic, procurement of 123I-MIBG has proved particularly challenging, necessitating the use of 68Ga-DOTATATE PET. 68Ga-DOTATATE is Food and Drug Administration–approved for imaging of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. Methods:68Ga-DOTATATE PET/CT imaging was performed for staging of 3 pediatric patients with neuroblastoma at our institution. A review of the literature was also completed. Results:68Ga-DOTATATE PET/CT scans were successfully performed on all patients. All patients showed 68Ga-DOTATATE–avid disease. PET scans showed an excellent spatial resolution and demonstrated high accuracy in concordance with current European Association of Nuclear Medicine guidelines. Conclusion: We have presented 68Ga-DOTATATE PET/CT imaging for staging of neuroblastoma and believe it can reliably be used as an alternative to 123I-MIBG. It has technical, clinical, and practical advantages making it an attractive option. Further multicenter studies are required before it can be recommended for standard clinical use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|